Modeling CIC::DUX4 sarcoma reveals oncogene-mediated MHCI-dependent immune evasion

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• CIC::DUX4 sarcoma (CDS) is an aggressive cancer with few treatments.
• Developing accurate models is crucial for understanding CDS and finding therapies.

Purpose of the Study:

• To create and characterize novel preclinical models of CDS.
• To investigate the molecular mechanisms of CDS immune evasion.
• To identify therapeutic targets for CDS.

Main Methods:

• Generated a doxycycline-inducible CIC::DUX4 chimeric mouse model.
• Developed the imChCDS cancer cell line from the mouse model.
• Analyzed tumor characteristics, gene expression, and immune responses.
• Investigated the role of P300/CBP co-activators and MHC class I (MHCI) expression.

Main Results:

• The mouse model and imChCDS cell line accurately recapitulate human CDS features.
• CIC::DUX4 expression drives tumorigenesis and metastasis.
• CDS tumors evade immune surveillance via CIC::DUX4/P300/CBP-mediated suppression of MHCI.
• Inactivating CIC::DUX4 or inhibiting P300/CBP restores MHCI, triggers anti-tumor immunity, and causes tumor regression.

Conclusions:

• The developed models provide a platform for CDS research.
• Targeting the CIC::DUX4/P300/CBP axis is a promising therapeutic strategy for CDS.
• Modulating the tumor microenvironment can overcome immune evasion in CDS.